Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.

@article{Kloner2011InvestigationalNU,
  title={Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.},
  author={Robert A. Kloner and Gary Comstock and Laurence A. Levine and Steven Tiger and Vera J. Stecher},
  journal={Expert opinion on pharmacotherapy},
  year={2011},
  volume={12 15},
  pages={2297-313}
}
INTRODUCTION At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food and Drug Administration approval only for the treatment of erectile dysfunction and pulmonary artery hypertension, for which their mechanism of action is vasodilation and augmentation of blood flow by impeding PDE5-mediated breakdown of cyclic guanosine monophosphate. However, these agents are also being investigated in a wide range of other potential medical and surgical applications for which current… CONTINUE READING

Similar Papers

Loading similar papers…